[Significance of vasoactive agents in the development of hypertrophic pulmonary osteoarthropathy].
D001163:Arteriovenous Anastomosis / Q000187:drug effects; D001920:Bradykinin / Q000009:adverse effects; D002199:Capillary Permeability / Q000187:drug effects; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D010004:Osteoarthropathy, Primary Hypertrophic / Q000139:chemically induced / Q000175:diagnosis; D010100:Oxygen / Q000097:blood; D011652:Pulmonary Circulation / Q000187:drug effects; D014665:Vasodilator Agents / Q000009:adverse effects*
D014665:Vasodilator Agents; D010100:Oxygen; D001920:Bradykinin
Die Bedeutung vasoaktiver Substanzen für die Entstehung der hypertrophen pulmonalen Osteoarthropathie.